ウイルスワクチンの市場規模、シェア、予測、動向分析：形態タイプ別、投与経路別、アプローチ別、適応症、包装別 - 2031年までの世界予測

ウイルスワクチン市場は2031年までに641億8,000万米ドルに達し、2024年から2031年までのCAGRは9.3%と予測されています。

ウイルスワクチンまたはウイルスベクターワクチンは、ウイルスベクターを使用して宿主に遺伝物質を導入し、ウイルス感染と闘う、またはウイルス感染から保護する免疫反応を誘発します。

この市場の成長は、予防接種プログラムに対する政府の関心の高まり、ワクチン投与の技術的進歩、手術や治療における不活化ワクチンの使用によってもたらされます。しかし、ワクチン開発には高いコストがかかり、ワクチン製造には長い期間がかかるため、この市場の成長は抑制されています。

さらに、治療用ワクチンへの注目の高まり、ワクチンにおけるアジュバントの使用の増加、新興市場での成長見込み、安定性が高くエネルギー効率の高い超低温フリーザーの開拓は、市場関係者に成長機会をもたらすと期待されています。しかし、製品回収やワクチンへの不十分なアクセスは、市場の成長に影響を与える大きな課題です。

本レポートでは、主要企業の製品ポートフォリオや地理的プレゼンス、過去3年間から4年間に採用された主要成長戦略についても幅広く評価しています。最近の動向として、ウイルスワクチン市場は有機的、無機的な戦略開拓をいくつか遂げています。本レポートで紹介する主要企業プロファイルは、Pfizer Inc.（米国）、GlaxoSmithKline plc（英国）、AstraZeneca plc （英国）、CSL Limited（オーストラリア）、Merck & Co., Inc. （米国）、Sanofi （フランス）、Sinovac Biotech Ltd.（中国）、Moderna, Inc.（米国）、Valneva SE（フランス）、Dynavax Technologies Corporation（米国）、EMERGENT BIOSOLUTIONS INC.（米国）、Johnson &Johnson（米国）、Bharat Biotech Ltd.（インド）、Serum Institute.（インド）、Serum Institute of India Pvt.（インド）です。

ワクチンにおけるアジュバントの使用の増加

従来の弱毒化ワクチンは、天然痘、麻疹、ポリオなど様々な適応症に有効であることが証明されています。しかし、これらのワクチンは発熱、発疹、ワクチン由来の感染症などの副作用を伴うことが多いです。さらに、大規模生産やワクチンの安定性に関する問題も大きな課題となっています。これらの問題に対処するため、強固な免疫応答を刺激するアジュバントワクチンが開発されました。

アジュバントワクチンは病原体のごく一部しか含まないため、免疫原性を低下させ、副作用を最小限に抑えることができます。ワクチン中のアジュバントは、以下のような様々な役割を果たします：

• 抗原をそのままの形で投与することにより、抗原に対する免疫反応を開始させます。
• ワンステップワクチン接種を容易にし、ワクチン接種コストを削減します。
• 免疫不全患者における免疫応答の増強します。

最近まで、アルミニウム含有アジュバントは、他のアジュバントを比較する際のゴールドスタンダードと考えられていました。しかし、最近の進歩により、これらのアジュバントの物理的、化学的、生物学的特性が改善され、ヒトにおける過敏反応、発がん性、催奇形性、毒性が減少しました。アジュバントシステムにもさまざまな改良が加えられています。例えば、水中油型エマルジョンベースのアジュバントは、その効果的で有望な結果から、ヒト用に開発されました。さらに、ビロソームワクチンはインフルエンザ治療用に特別に設計され、有効性、品質、長期にわたる免疫応答を提供しています。現在進行中の調査では、ワクチンの有効性を高めるために、古典的なアジュバント、免疫賦活剤、あるいはその組み合わせなど、最適なアジュバントを選択することに焦点が当てられています。その結果、アジュバントの研究と利用における進歩は、ワクチンメーカーに新たな成長機会をもたらしています。

本レポートで調査した形態のうち、2024年には凍結乾燥ワクチン分野がウイルスワクチン市場で最も高いCAGR11.1%を記録すると予測されます。凍結乾燥ウイルスワクチンは、余分な水分を除去する凍結乾燥工程を経て保存され、安定性を高め、保存期間を延ばし、輸送を容易にします。これらのワクチンは、黄熱病、麻疹、流行性耳下腺炎、風疹、その他のウイルス性疾患などの感染予防に一般的に使用されており、安定性や輸送性の向上といった利点があります。

本レポートで調査したワクチンの種類のうち、2024年にはウイルスベクターワクチンの分野がウイルスワクチン市場のCAGR17%で最も高くなると予測されます。ウイルスベクターワクチンは、遺伝子組み換えウイルスを用いて細胞に遺伝物質を導入し、免疫反応を引き起こすウイルスタンパク質の産生を促すものです。これらのワクチンには、強力な免疫反応、迅速な開発と拡張性、幅広い有効性、多価ワクチンの可能性など、いくつかの利点があります。

本レポートで調査したアプローチのうち、2024年には予防ワクチン分野がウイルスワクチン市場で最も高いCAGRを記録すると予測されます。この成長は、慢性疾患や感染症の流行増加、予防接種に対する一般市民の意識の高まり、予防接種プログラムの拡大といった要因によってもたらされます。例えば、2024年2月、インドの財務・企業問題担当連邦大臣は、9歳から14歳の女児の子宮頸がん予防を目的としたViksit Bharat by 2047キャンペーンの下でのワクチン接種プログラムを提案しました。

本レポートで調査した適応症のうち、2024年には、がん分野がウイルスワクチン市場で最も高いCAGR24.1%を記録する予定です。GLOBOCANによると、2022年に新たに報告されたがん症例数は2,000万件で、2030年には2,410万件に増加すると予測されています。がんの有病率の増加は、人間の苦痛と経済的負担を軽減する予防技術の必要性を浮き彫りにしています。ワクチンは、前悪性状態やがんの一次予防において、また根治的治療を受けた患者の再発を抑える二次予防において、重要な役割を果たしています。

本レポートで調査した投与経路のうち、2024年には筋肉内投与がウイルスワクチン市場で最大のシェアを占めると予想されます。患者の筋肉にワクチンを投与する筋肉内投与は、安全性、忍容性、様々な種類のワクチンとの適合性に加え、強力な免疫反応を引き起こすことができるため、好まれています。

本レポートで調査した包装タイプのうち、2024年にはバイアルセグメントがウイルスワクチン市場で最も高いCAGRを記録すると予測されます。プラスチックまたはガラス製のバイアルは、液体または粉末の薬剤を包装するために使用される小型容器です。バイアルはウイルスワクチンに保護環境を提供し、湿気、光、汚染などの外的要因からワクチンを保護することで、安定性と有効性を維持するのに役立ちます。

本レポートで調査した地域の中では、アジア太平洋がウイルスワクチン市場で最も高いCAGR 10.2%を記録する予定です。この成長の主な要因は、感染症の流行増加、ワクチンや予防接種に対する一般市民の意識の高まり、政府の取り組み、高いヘルスケア支出、可処分所得の増加などです。例えば、2024年4月、Wockhardt Hospitals（インド）は、予防接種の重要性を強調するため、あらゆる年齢層の人々を対象とした予防接種プログラムを開始しました。

調査範囲：

ウイルスワクチン市場：形態別

• 液体ワクチン
• 凍結乾燥ワクチン

ウイルスワクチン市場：ワクチンタイプ別

• サブユニット＆コンジュゲートワクチン
• 生ワクチン
• 不活化ワクチン
• mRNAワクチン
• ウイルスベクターワクチン
• トキソイド・ワクチン
• 混合ワクチン

ウイルスワクチン市場：投与経路別

• 筋肉内（IM）
• 皮下（SC）
• 経口
• その他の投与経路

（その他のウイルスにはノロウイルス、DNAウイルスが含まれます）

ウイルスワクチン市場：アプローチ別

• 予防ワクチン
• 治療用ワクチン

ウイルスワクチン市場：適応症別

• インフルエンザ
• ヒト乳頭腫ウイルス（HPV）
• ロタウイルス
• ポリオ
• 肝炎
• がん
• その他の適応症

（その他の適応症には、水痘、帯状疱疹ワクチン、クロレラ、重症急性呼吸器症候群、狂犬病などが含まれます）

ウイルスワクチン市場：包装別

• バイアル
• プレフィルドシリンジ

ウイルスワクチン市場：地域別

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • スイス
  • アイルランド
  • デンマーク
  • ベルギー
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
• 中東・アフリカ

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場洞察

• 市場概要
• 市場成長に影響を与える要因
  • 促進要因
    • 予防接種プログラムに対する政府の関心の高まり
    • ワクチン投与における技術の進歩
  • 抑制要因
    • ワクチン開発コストの高さ
    • ワクチン製造の長期化
  • 機会
    • 治療用ワクチンへの注目の高まり
    • ワクチンにおけるアジュバントの使用の増加
    • 新興市場における成長見通し
  • 課題
    • 製品回収
    • ワクチンへの不十分なアクセス
  • 主要動向
    • 個別化ワクチンとワクチノミクス
    • 予防接種に関するメディアと市民の意識
• 規制分析
• 価格分析
• ポーターのファイブフォース分析
• パイプライン分析

第5章 ウイルスワクチン市場の評価：形態別

• 概要
• 液体ウイルスワクチン
• 凍結乾燥ウイルスワクチン

第6章 ウイルスワクチン市場：ワクチンタイプ別

• 概要
• mRNAワクチン
• サブユニット＆コンジュゲートワクチン
• 生ワクチン
• 不活化ワクチン
• ウイルスベクター・ワクチン
• 混合ワクチン

第7章 ウイルスワクチン市場の評価：投与経路別

• 概要
• 筋肉内（IM）
• 皮下（SC）
• 経口
• その他の投与経路

第8章 ウイルスワクチン市場の評価：アプローチ別

• 概要
• 予防ワクチン
• 治療用ワクチン

第9章 ウイルスワクチン市場の評価：適応症別

• 概要
• インフルエンザ
• ヒトパピローマウイルス（HPV）
• ロタウイルス
• ポリオ
• 肝炎
• がん
• その他の適応症

第10章 ウイルスワクチン市場の評価：包装別

• 概要
• バイアル
• プレフィルドシリンジ

第11章 コロナウイルス疾患

• COVID-19：概要
• コロナウイルスの有病率
• COVID-19の市場評価

第12章 ウイルスワクチン市場の評価：地域別

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • スイス
  • アイルランド
  • デンマーク
  • ベルギー
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
• 中東・アフリカ

第13章 競合情勢

• イントロダクション
• 主要成長戦略
• 競合ベンチマーキング
• 競合ダッシュボード
  • 業界リーダー
  • 市場差別化要因
  • 先行企業
  • 新興企業
• 市場シェア分析

第14章 企業プロファイル

• Pfizer Inc.
• Glaxo Smith Kline plc
• AstraZeneca plc
• CSL Limited
• Merck & Co., Inc.
• Moderna, Inc.
• Johnson & Johnson
• Emergent Biosolutions Inc.
• Bharat Biotech Ltd.
• Sinovac Biotech Ltd.
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Dynavax Technologies Corporation
• Valneva SE

第15章 付録

LIST OF TABLES

• Table 1 Estimated Number of Malaria Cases in Regions with Emerging Countries, 2022 (in Thousands)
• Table 2 Number of People Living with HIV, by Region, 2022 (in Million)
• Table 3 Key Government Agencies Regulating Vaccines
• Table 4 Average Selling Prices of Key Vaccines, by Region (USD/UNIT)
• Table 5 Viral Vaccines: Pipeline Analysis
• Table 6 Global Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 7 Global Liquid Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 8 Companies Offering Lyophilized Viral Vaccines
• Table 9 Global Lyophilized Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 10 Global Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 11 Companies Offering mRNA Vaccines
• Table 12 Global mRNA Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 13 Companies Offering Subunit and Conjugate Vaccines
• Table 14 Global Subunit & Conjugate Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 15 Companies Offering Live-Attenuated Vaccines
• Table 16 Global Live-Attenuated Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 17 Key Companies Offering Inactivated Vaccines
• Table 18 Global Inactivated Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 19 Global Viral Vector Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 20 Key Companies Offering Combination Vaccines
• Table 21 Global Combination Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 22 Global Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 23 Intramuscular Sites For Vaccine Administration, by Age Group
• Table 24 Global Intramuscular Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 25 Subcutaneous Sites For Vaccine Administration, by Age Group
• Table 26 Global Subcutaneous Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 27 Key Companies Offering Oral Viral Vaccines
• Table 28 Global Oral Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 29 Global Viral Vaccines Market for Other Routes of Administration, by Country/Region, 2022-2031 (USD Million)
• Table 30 Global Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 31 Global Preventive Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 32 Global Therapeutic Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 33 Global Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 34 Global Viral Vaccines Market For Influenza, by Country/Region, 2022-2031 (USD Million)
• Table 35 Global Viral Vaccines Market For Human Papillomavirus (HPV), by Country/Region, 2022-2031 (USD Million)
• Table 36 Global Viral Vaccines Market For Rotavirus, by Country/Region, 2022-2031 (USD Million)
• Table 37 Global Viral Vaccines Market For Poliomyelitis, by Country/Region, 2022-2031 (USD Million)
• Table 38 Global Viral Vaccines Market For Hepatitis, by Country/Region, 2022-2031 (USD Million)
• Table 39 Global NUMBER of New Cancer Cases, 2022-2030
• Table 40 Global Viral Vaccines Market For Cancer, by Country/Region, 2022-2031 (USD Million)
• Table 41 Global Viral Vaccines Market For Other Indications, by Country/Region, 2022-2031 (USD Million)
• Table 42 Global Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 43 Global Viral Vaccine Vials Market, by Country/Region, 2022-2031 (USD Million)
• Table 44 Global Prefilled Viral Vaccine Syringes Market, by Country/Region, 2022-2031 (USD Million)
• Table 45 COVID-19: Overview
• Table 46 Coronavirus Confirmed Cases, by Region (As of April 2024)
• Table 47 Global Viral Vaccines Market FOR COVID-19, by Country/Region, 2022-2031 (USD Million)
• Table 48 Global Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 49 North America: Viral Vaccines Market, by Country, 2022-2031 (USD Million)
• Table 50 North America: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 51 North America: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 52 North America: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 53 North America: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 54 North America: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 55 North America: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 56 U.S.: Accelerated Approval Dates of Vaccines By The U.S. FDA
• Table 57 U.S.: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 58 U.S.: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 59 U.S.: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 60 U.S.: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 61 U.S.: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 62 U.S.: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 63 Canada: Influenza Cases, 2023-2024, Week 1-34
• Table 64 Canada: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 65 Canada: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 66 Canada: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 67 Canada: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 68 Canada: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 69 Canada: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 70 Europe: Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 71 Europe: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 72 Europe: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 73 Europe: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 74 Europe: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 75 Europe: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 76 Europe: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 77 Germany: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 78 Germany: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 79 Germany: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 80 Germany: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 81 Germany: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 82 Germany: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 83 U.K.: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 84 U.K.: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 85 U.K.: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 86 U.K.: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 87 U.K.: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 88 U.K.: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 89 France: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 90 France: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 91 France: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 92 France: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 93 France: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 94 France: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 95 Italy: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 96 Italy: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 97 Italy: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 98 Italy: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 99 Italy: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 100 Italy: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 101 Spain: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 102 Spain: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 103 Spain: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 104 Spain: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 105 Spain: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 106 Spain: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 107 Switzerland: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 108 Switzerland: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 109 Switzerland: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 110 Switzerland: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 111 Switzerland: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 112 Switzerland: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 113 Ireland: Number of Infectious Diseases Notifications (2019-2023)
• Table 114 Ireland: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 115 Ireland: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 116 Ireland: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 117 Ireland: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 118 Ireland: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 119 Ireland: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 120 Denmark: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 121 Denmark: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 122 Denmark: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 123 Denmark: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 124 Denmark: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 125 Denmark: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 126 Belgium: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 127 Belgium: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 128 Belgium: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 129 Belgium: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 130 Belgium: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 131 Belgium: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 132 Rest of Europe: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 133 Rest of Europe: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 134 Rest of Europe: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 135 Rest of Europe: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 136 Rest of Europe: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 137 Rest of Europe: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 138 Asia-Pacific: Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 139 Asia-Pacific: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 140 Asia-Pacific: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 141 Asia-Pacific: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 142 Asia-Pacific: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 143 Asia-Pacific: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 144 Asia-Pacific: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 145 Japan: Key Macroindicators & Microindicators
• Table 146 Japan: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 147 Japan: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 148 Japan: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 149 Japan: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 150 Japan: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 151 Japan: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 152 China: Key Macroindicators & Microindicators
• Table 153 China: Key Immunization Indicators
• Table 154 China: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 155 China: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 156 China: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 157 China: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 158 China: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 159 China: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 160 India: Key Macroindicators & Microindicators
• Table 161 India: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 162 India: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 163 India: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 164 India: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 165 India: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 166 India: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 167 South Korea: Key Macroindicators & Microindicators
• Table 168 South Korea: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 169 South Korea: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 170 South Korea: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 171 South Korea: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 172 South Korea: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 173 South Korea: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 174 Bangladesh: Key Immunization Indicators
• Table 175 Nepal: Key Immunization Indicators
• Table 176 Rest of Asia-Pacific: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 177 Rest of Asia-Pacific: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 178 Rest of Asia-Pacific: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 179 Rest of Asia-Pacific: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 180 Rest of Asia-Pacific: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 181 Latin America: Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
• Table 182 Latin America: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 183 Latin America: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 184 Latin America: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 185 Latin America: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 186 Latin America: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 187 Latin America: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 188 Brazil: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 189 Brazil: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 190 Brazil: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 191 Brazil: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 192 Brazil: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 193 Brazil: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 194 Mexico: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 195 Mexico: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 196 Mexico: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 197 Mexico: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 198 Mexico: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 199 Mexico: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 200 Rest of Latin America: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 201 Rest of Latin America: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 202 Rest of Latin America: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 203 Rest of Latin America: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 204 Rest of Latin America: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 205 Rest of Latin America: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 206 Middle East & Africa: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
• Table 207 Middle East & Africa: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
• Table 208 Middle East & Africa: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
• Table 209 Middle East & Africa: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
• Table 210 Middle East & Africa: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
• Table 211 Middle East & Africa: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
• Table 212 Recent Developments, by Company (2021-2024)

LIST OF FIGURES

• Figure 1 Research Process
• Figure 2 Secondary Sources Referenced for this Study
• Figure 3 Primary Research Techniques
• Figure 4 Key Executives Interviewed
• Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
• Figure 6 Market Sizing and Growth Forecast Approaches
• Figure 7 Global Viral Vaccines Market, by Indication, 2024 Vs.2031 (USD Million)
• Figure 8 Global Viral Vaccines Market, by Form, 2024 Vs. 2031 (USD Million)
• Figure 9 Global Viral Vaccines Market, by Vaccine Type, 2024 Vs. 2031 (USD Million)
• Figure 10 Global Viral Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
• Figure 11 Global Viral Vaccines Market, by Approach, 2024 Vs. 2031 (USD Million)
• Figure 12 Global Viral Vaccines Market, by Packaging, 2024 Vs. 2031 (USD Million)
• Figure 13 Global Viral Vaccines Market, by Geography
• Figure 14 Impact Analysis of Market Dynamics
• Figure 15 Porter's Five Forces Analysis
• Figure 16 Global Viral Vaccines Market, by Form, 2024 Vs. 2031 (USD Million)
• Figure 17 Global Viral Vaccines Market, by Vaccine Type, 2024 Vs. 2031 (USD Million)
• Figure 18 Global Viral Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
• Figure 19 Global Viral Vaccines Market, by Approach, 2024 VS. 2031 (USD Million)
• Figure 20 Global Viral Vaccines Market, by Indication, 2024 VS. 2031 (USD Million)
• Figure 21 Global Viral Vaccines Market, by Packaging, 2024 VS. 2031 (USD Million)
• Figure 22 Global Viral Vaccines Market, by GEOGRAPHY, 2024 VS. 2031 (USD Million)
• Figure 23 North America: Viral Vaccines Market Snapshot
• Figure 24 Europe: Viral Vaccines Market Snapshot
• Figure 25 Asia-Pacific: Viral Vaccines Market Snapshot
• Figure 26 Number of Cases Reported for Dengue, 2019-2023
• Figure 27 Latin America: Viral Vaccines Market Snapshot
• Figure 28 Saudi Arabia Viral Vaccination Coverage (2023)
• Figure 29 Key Growth Strategies Adopted By Leading Players, 2021-2024
• Figure 30 Viral Vaccines Market: Competitive Benchmarking (Based On Indications)
• Figure 31 Viral Vaccines Market: Competitive Benchmarking (BASED ON Region)
• Figure 32 Competitive Dashboard: Viral Vaccines Market
• Figure 33 Market Share Analysis: Viral Vaccines Market (with Covid-19 Vaccines), 2023
• Figure 34 Market Share Analysis: Viral Vaccines Market (Without Covid-19 Vaccines), 2023
• Figure 35 Pfizer Inc.: Financial Snapshot (2023)
• Figure 36 Glaxo Smith Kline Plc: Financial Overview (2023)
• Figure 37 AstraZeneca Plc: Financial Overview (2023)
• Figure 38 CSL LIMITED: Financial Overview (2024)
• Figure 39 Merck & Co., Inc.: Financial Overview (2023)
• Figure 40 Moderna, Inc.: Financial Snapshot (2023)
• Figure 41 Johnson & Johnson: Financial Snapshot (2023)
• Figure 42 Emergent Biosolutions Inc.: Financial Snapshot (2023)
• Figure 43 Sinovac Biotech Ltd.: Financial Overview (2023)
• Figure 44 Sanofi: Financial Overview (2023)
• Figure 45 Dynavax Technologies Corporation: Financial Snapshot (2023)
• Figure 46 Valneva SE: Financial Snapshot (2023)

Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated), Route of Administration (Intramuscular, Subcutaneous, Oral), Approach, Indication, Packaging - Global Forecast to 2031

According to a new market research report, 'Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated), Route of Administration (Intramuscular, Subcutaneous, Oral), Approach, Indication, Packaging - Global Forecast to 2031', published by Meticulous Research(R), the viral vaccines market is projected to reach $64.18 billion by 2031, at a CAGR of 9.3% from 2024 to 2031.

Viral vaccines or viral vector vaccines use a viral vector to deliver genetic material into the host to elicit an immune response to fight or protect against viral infections.

The growth of this market is driven by the increasing government focus on immunization programs, technological advances in vaccine administration, and the use of inactivated vaccines in surgeries and treatments. However, the high costs of vaccine development and the long timelines of vaccine manufacturing restrain the growth of this market.

Furthermore, the growing focus on therapeutic vaccines, this increasing use of adjuvants in vaccines, growth prospects in emerging markets, and the development of highly stable and energy-efficient ultra-low-temperature freezers are expected to generate growth opportunities for market stakeholders. However, product recalls and inadequate access to vaccines are major challenges impacting the market's growth.

The report also includes an extensive assessment of the leading players' product portfolio and geographic presence and the key growth strategies adopted by them over the past three to four years. In recent years, the viral vaccines market has witnessed several organic and inorganic strategic developments. The key players profiled in the viral vaccines market report are Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), CSL Limited (Australia), Merck & Co., Inc. (U.S.), Sanofi (France), Sinovac Biotech Ltd. (China), Moderna, Inc. (U.S.), Valneva SE (France), Dynavax Technologies Corporation (U.S.), EMERGENT BIOSOLUTIONS INC. (U.S.), Johnson & Johnson (U.S.), Bharat Biotech Ltd. (India), and Serum Institute of India Pvt. Ltd. (India).

Increasing Use of Adjuvants in Vaccines

Conventional live-attenuated vaccines have proven effective for various indications, such as smallpox, measles, and polio, in most cases. However, these vaccines often come with side effects, including fever, rashes, and vaccine-derived infections. Additionally, large-scale production and issues related to vaccine consistency present significant challenges. To address these issues, adjuvant vaccines, which stimulate robust immune responses, were developed.

Adjuvant vaccines contain only a small part of the pathogen, which helps reduce immunogenicity and minimizes side effects. Adjuvants in vaccines serve various purposes, including:

• Initiating the immune response to antigens by delivering them in their native form.
• Facilitating single-step vaccination, thereby reducing vaccination costs.
• Enhancing immune responses in immunocompromised individuals.

Until recently, aluminum-containing adjuvants were considered the gold standard for comparing other adjuvants. However, recent advancements have improved the physical, chemical, and biological properties of these adjuvants, reducing hypersensitivity reactions, carcinogenicity, teratogenicity, and toxicity in humans. Various modifications to adjuvant systems have also been made. For instance, oil-in-water emulsion-based adjuvants have been developed for human use due to their effective and promising results. Additionally, virosome vaccines have been specifically designed for influenza treatment, offering effectiveness, quality, and long-lasting immune responses. Ongoing research is focused on selecting the best adjuvants-whether classical adjuvants, immunostimulants, or combinations-to enhance vaccine efficacy. As a result, advancements in adjuvant research and utilization present new growth opportunities for vaccine manufacturers.

The viral vaccines market is segmented by Form (Liquid Vaccines, Lyophilized Vaccines), Vaccine Type (mRNA Vaccines, Live-attenuated Vaccines, Inactivated Vaccines, Viral Vector Vaccines, Subunit & Conjugate Vaccines, Toxoid Vaccines, Combination Vaccines), Route of Administration (Intramuscular (IM), Subcutaneous (SC), Oral, and Other Routes of Administration), Approach (Preventive Vaccines, Therapeutic Vaccines), Indication (Influenza, Human Papilloma Virus (HPV), Rotavirus, Poliomyelitis (Polio), Hepatitis, Cancer, and Other Indications), Packaging (Vials, Prefilled Syringes) and Geography.

Among the forms studied in this report, in 2024, the lyophilized vaccines segment is slated to register the highest CAGR of 11.1% of the viral vaccines market. Lyophilized viral vaccines are preserved through a freeze-drying process that removes excess water, enhancing their stability, extending shelf life, and making transportation easier. These vaccines are commonly used to prevent infections such as yellow fever, measles, mumps, rubella, and other viral diseases, offering advantages such as improved stability and transportability.

Among the vaccine types studied in this report, in 2024, the viral vector vaccines segment is slated to register the highest CAGR of 17% of the viral vaccines market. Viral vector vaccines use modified viruses to deliver genetic material into cells, prompting them to produce viral proteins that trigger an immune response. These vaccines offer several benefits, including a strong immune response, rapid development and scalability, broad effectiveness, and the potential for creating multivalent vaccines.

Among the approaches studied in this report, in 2024, the preventive vaccines segment is slated to register the highest CAGR of the viral vaccines market. This growth is driven by factors such as the increasing prevalence of chronic and infectious diseases, rising public awareness of immunization, and the expansion of immunization programs. For instance, in February 2024, the Union Minister for Finance & Corporate Affairs of India proposed a vaccination program under the Viksit Bharat by 2047 campaign aimed at preventing cervical cancer in girls aged 9 to 14.

Among the indications studied in this report, in 2024, the cancer segment is slated to register the highest CAGR of 24.1% of the viral vaccines market. Cancer prevalence is rising globally; according to GLOBOCAN, 20.0 million new cancer cases were reported in 2022, with this number projected to increase to 24.1 million by 2030. The growing prevalence of cancer highlights the need for preventive techniques to reduce human suffering and financial burdens. Vaccines play a crucial role in first-line prevention of premalignant conditions and cancer, as well as in secondary prevention for patients who have undergone curative treatments to reduce recurrence.

Among the routes of administration studied in this report, in 2024, the intramuscular segment is expected to account for the largest share of the viral vaccines market. The IM route, which involves administering vaccines into a patient's muscles, is preferred due to its ability to elicit a strong immune response, along with its safety, tolerability, and compatibility with various vaccine types.

Among the packaging types studied in this report, in 2024, the vials segment is slated to register the highest CAGR of the viral vaccines market. Vials, made from plastic or glass, are small containers used to package liquid or powdered medications. They provide a protective environment for viral vaccines, helping to maintain stability and efficacy by shielding the vaccines from external factors like moisture, light, and contamination.

Among the regions studied in this report, Asia-Pacific is slated to register the highest CAGR of 10.2% of the viral vaccines market. This growth is primarily attributed to the increasing prevalence of infectious diseases, growing public awareness of vaccines and immunization, government initiatives, high healthcare expenditure, and rising disposable incomes. For instance, in April 2024, Wockhardt Hospitals (India) launched an immunization program aimed at people of all age groups to emphasize the importance of vaccination.

Scope of the Report:

Viral Vaccines Market-by Form

• Liquid Vaccines
• Lyophilized Vaccines

Viral Vaccines Market-by Vaccine Type

• Subunit & Conjugate Vaccines
• Live-attenuated Vaccines
• Inactivated Vaccines
• mRNA Vaccines
• Viral Vector Vaccines
• Toxoid Vaccines
• Combination Vaccines

Viral Vaccines Market-by Route of Administration

• Intramuscular (IM)
• Subcutaneous (SC)
• Oral
• Other Routes of Administration

(Other virus types include norovirus and DNA viruses)

Viral Vaccines Market-by Approach

• Preventive Vaccines
• Therapeutic Vaccines

Viral Vaccines Market-by Indication

• Influenza
• Human Papilloma Virus (HPV)
• Rotavirus
• Poliomyelitis (Polio)
• Hepatitis
• Cancer
• Other Indications

(Other indications include varicella, herpes zoster vaccines, chlorella, severe acute respiratory syndrome, and rabies diseases)

Viral Vaccines Market-by Packaging

• Vials
• Prefilled Syringes

Viral Vaccines Market-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Switzerland
  • Ireland
  • Denmark
  • Belgium
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders From The Industry
• 2.3. Market Sizing & Forecasting
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
• 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Drivers
    • 4.2.1.1. Increasing Government Focus on Immunization Programs
    • 4.2.1.2. Technological Advancements in Vaccine Administration
  • 4.2.2. Restraints
    • 4.2.2.1. High Costs of Vaccine Development
    • 4.2.2.2. Long Timelines of Vaccine Manufacturing
  • 4.2.3. Opportunities
    • 4.2.3.1. Growing Focus on Therapeutic Vaccines
    • 4.2.3.2. Increasing Use of Adjuvants in Vaccines
    • 4.2.3.3. Growth Prospects in Emerging Markets
  • 4.2.4. Challenges
    • 4.2.4.1. Product Recalls
    • 4.2.4.2. Inadequate Access to Vaccines
  • 4.2.5. Key Trends
    • 4.2.5.1. Personalized Vaccines and Vaccinomics
    • 4.2.5.2. Media and Public Awareness Regarding Immunization
• 4.3. Regulatory Analysis
• 4.4. Pricing Analysis
• 4.5. Porter's Five Forces Analysis
  • 4.5.1. Bargaining Power of Buyers
  • 4.5.2. Bargaining Power of Suppliers
  • 4.5.3. Threat of Substitutes
  • 4.5.4. Threat of New Entrants
  • 4.5.5. Degree of Competition
• 4.6. Pipeline Analysis

5. Viral Vaccines Market Assessment-by Form

• 5.1. Overview
• 5.2. Liquid Viral Vaccines
• 5.3. Lyophilized Viral Vaccines

6. Viral Vaccines Market-by Vaccine Type

• 6.1. Overview
• 6.2. mRNA Vaccines
• 6.3. Subunit & Conjugate Vaccines
• 6.4. Live-attenuated Vaccines
• 6.5. Inactivated Vaccines
• 6.6. Viral Vector Vaccines
• 6.7. Combination Vaccines

7. Viral Vaccines Market Assessment-by Route of Administration

• 7.1. Overview
• 7.2. Intramuscular (IM)
• 7.3. Subcutaneous (SC)
• 7.4. Oral
• 7.5. Other Routes of Administration

8. Viral Vaccines Market Assessment-by Approach

• 8.1. Overview
• 8.2. Preventive Vaccines
• 8.3. Therapeutic Vaccines

9. Viral Vaccines Market Assessment-by Indication

• 9.1. Overview
• 9.2. Influenza
• 9.3. Human Papillomavirus (HPV)
• 9.4. Rotavirus
• 9.5. Poliomyelitis (Polio)
• 9.6. Hepatitis
• 9.7. Cancer
• 9.8. Other Indications

10. Viral Vaccines Market Assessment-by Packaging

• 10.1. Overview
• 10.2. Vials
• 10.3. Prefilled Syringes

11. Coronavirus Disease

• 11.1. COVID-19: Overview
• 11.2. Coronavirus Prevalence
• 11.3. COVID-19 Market Assessment

12. Viral Vaccines Market Assessment-by Geography

• 12.1. Overview
• 12.2. North America
  • 12.2.1. U.S.
  • 12.2.2. Canada
• 12.3. Europe
  • 12.3.1. Germany
  • 12.3.2. U.K.
  • 12.3.3. France
  • 12.3.4. Italy
  • 12.3.5. Spain
  • 12.3.6. Switzerland
  • 12.3.7. Ireland
  • 12.3.8. Denmark
  • 12.3.9. Belgium
  • 12.3.10. Rest of Europe
• 12.4. Asia-Pacific
  • 12.4.1. Japan
  • 12.4.2. China
  • 12.4.3. India
  • 12.4.4. South Korea
  • 12.4.5. Rest of Asia-Pacific
• 12.5. Latin America
  • 12.5.1. Brazil
  • 12.5.2. Mexico
  • 12.5.3. Rest of Latin America
• 12.6. Middle East & Africa

13. Competitive Landscape

• 13.1. Introduction
• 13.2. Key Growth Strategies
• 13.3. Competitive Benchmarking
• 13.4. Competitive Dashboard
  • 13.4.1. Industry Leaders
  • 13.4.2. Market Differentiators
  • 13.4.3. Vanguards
  • 13.4.4. Emerging Companies
• 13.5. Market Share Analysis

14. Company Profiles

• 14.1. Pfizer Inc.
• 14.2. Glaxo Smith Kline plc
• 14.3. AstraZeneca plc
• 14.4. CSL Limited
• 14.5. Merck & Co., Inc.
• 14.6. Moderna, Inc.
• 14.7. Johnson & Johnson
• 14.8. Emergent Biosolutions Inc.
• 14.9. Bharat Biotech Ltd.
• 14.10. Sinovac Biotech Ltd.
• 14.11. Sanofi
• 14.12. Serum Institute of India Pvt. Ltd.
• 14.13. Dynavax Technologies Corporation
• 14.14. Valneva SE

15. Appendix

• 15.1. Available Customization
• 15.2. Related Reports